Ovarian Cancer Clinical Roundup
(Yahoo! Finance) Aug 12, 2020 - VBL Therapeutics announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned interim analysis in the ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111) in patients with platinum-resistant ovarian cancer, and unanimously...
(ESMO) Aug 12, 2020 - Findings from the INSPIRE, a prospective phase II clinical trial to assess circulating tumour DNA (ctDNA) in five cohorts of patients with advanced solid tumours treated with pembrolizumab, demonstrate the potential for broad clinical utility of ctDNA-based surveillance in patients treated with immune checkpoint...
(Markets Insider) Aug 11, 2020 - Mersana Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for XMT-1536, for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic therapy or patients who...
(Roswell Park) Aug 5, 2020 - "The short answer is yes," says gynecologic oncologist Peter Frederick, MD, FACOG, Associate Professor and Clinical Chief of Gynecology at Roswell Park.
(NCI/Cancer Currents Blog) July 30, 2020 - A microRNA—a molecule made by cells to turn genes on and off—called miR-181a may help high-grade serous ovarian cancer form, a study has found. The scientists think the microRNA could potentially help doctors detect ovarian cancer earlier.
(J Clin Oncol) - 2020-08-13
(Br J Cancer) - 2020-08-11
(Lancet Oncol) - 2020-08-06
(J Natl Cancer Inst) - 2020-08-07
(J Clin Oncol) - 2020-08-04
Dr. Slomovitz, Professor of Obstetrics and Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, Dr. Wenham, Gynecologic Oncologist, Moffit Cancer Center, and Dr. Morrissey, Obstetrics and Gynecology, Women's Health Institute Cleveland Clinic Weston, discuss COVID-19 pertaining to ovarian cancer